VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Oriental Land Co., Ltd. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Oriental Land Co., Ltd.
4661 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Oriental Land Co., Ltd.'s moat claims, evidence, and risks.
View 4661 analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Oriental Land Co., Ltd. leads (95 / 100 vs 70 / 100 for Amgen Inc.).
- Segment focus: Oriental Land Co., Ltd. has 3 segments (81.3% in Theme Park Segment); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Duopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: Oriental Land Co., Ltd. has 5 moat types across 4 domains; Amgen Inc. has 5 across 3.
Primary market context
Oriental Land Co., Ltd.
Theme Park Segment
Large-scale destination theme parks in Japan (Tokyo Disney Resort parks: Tokyo Disneyland and Tokyo DisneySea)
Japan (with inbound tourism)
Consumers (domestic residents and inbound tourists), plus group/agency channels
Owner/operator of theme parks under licensed IP
81.3%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Oriental Land Co., Ltd. strengths
Amgen Inc. strengths
Segment mix
Oriental Land Co., Ltd. segments
Full profile >Theme Park Segment
Duopoly
Hotel Business Segment
Oligopoly
Other Business Segment
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.